Neoleukin Therapeutics

Company Profile

Neoleukin Therapeutics had its IPO on 2014-03-07 under the ticker symbol NLTX.

The company operates in the Healthcare sector and Biotechnology industry. Neoleukin Therapeutics has a staff strength of 7 employees.

Stock update

Shares of Neoleukin Therapeutics opened at $0.76 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.73 - $0.76, and closed at $0.73.

This is a +0.01% increase from the previous day's closing price.

A total volume of 50,446 shares were traded at the close of the day’s session.

In the last one week, shares of Neoleukin Therapeutics have slipped by -2.78%.

Neoleukin Therapeutics's Key Ratios

Neoleukin Therapeutics has a market cap of $33.06 million, indicating a price to book ratio of 0.1855 and a price to sales ratio of 0.

In the last 12-months Neoleukin Therapeutics’s revenue was $0 with a gross profit of $0 and an EBITDA of $-41546000. The EBITDA ratio measures Neoleukin Therapeutics's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Neoleukin Therapeutics’s operating margin was 0% while its return on assets stood at -23.07% with a return of equity of -43.62%.

In Q2, Neoleukin Therapeutics’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Neoleukin Therapeutics’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.77 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Neoleukin Therapeutics’s profitability.

Neoleukin Therapeutics stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.3099. Its price to sales ratio in the trailing 12-months stood at 0.

Neoleukin Therapeutics stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$94.01 million

Total Liabilities

$4.88 million

Operating Cash Flow

$-411000.00

Capital Expenditure

$132000

Dividend Payout Ratio

0%

Neoleukin Therapeutics ended 2024 with $94.01 million in total assets and $0 in total liabilities. Its intangible assets were valued at $94.01 million while shareholder equity stood at $79.58 million.

Neoleukin Therapeutics ended 2024 with $0 in deferred long-term liabilities, $4.88 million in other current liabilities, in common stock, $-467344000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $31.11 million and cash and short-term investments were $82.06 million. The company’s total short-term debt was $1,493,000 while long-term debt stood at $0.

Neoleukin Therapeutics’s total current assets stands at $83.78 million while long-term investments were $0 and short-term investments were $50.95 million. Its net receivables were $0 compared to accounts payable of $3.39 million and inventory worth $0.

In 2024, Neoleukin Therapeutics's operating cash flow was $-411000.00 while its capital expenditure stood at $132000.

Comparatively, Neoleukin Therapeutics paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.73

52-Week High

$1.04

52-Week Low

$0.375

Analyst Target Price

$1.5

Neoleukin Therapeutics stock is currently trading at $0.73 per share. It touched a 52-week high of $1.04 and a 52-week low of $1.04. Analysts tracking the stock have a 12-month average target price of $1.5.

Its 50-day moving average was $0.73 and 200-day moving average was $0.68 The short ratio stood at 0.22 indicating a short percent outstanding of 0%.

Around 1771% of the company’s stock are held by insiders while 3478.3% are held by institutions.